(6-(cyclohexylamino)-1,3-dimethyl-5(2-pyridyl)furo[2,3-d]pyrimidine-2,4(1H,3H)-dione) abbreviated as CDP was synthesized and characterized. Ti(IV), Zn(II), Fe(III), and Pd(II) metal complexes of this ligand are prepared by the reaction of salts of Ti(IV), Zn(II), Fe(III), and Pd(II) with CDP in acetonitrile. Characterization of the ligand and its complexes was made by microanalyses, FT-IR, (1)H NMR, (13)C NMR, and UV-Visible spectroscopy. All complexes were characterized by several techniques using elemental analysis (C, H, N), FT-IR, electronic spectra, and molar conductance measurements. The elemental analysis data suggest the stoichiometry to be 1:1 [M:L] ratio formation. The molar conductance measurements reveal the presence of 1:1 electrolytic nature complexes. These new complexes showed excellent antitumor activity against two kinds of cancer cells that are K562 (human chronic myeloid leukemia) cells and Jurkat (human T lymphocyte carcinoma) cells.

中文翻译：

---

6-(环己基氨基)-1, 3-二甲基-5(2-吡啶基)呋喃[2,3-d]嘧啶-2,4(1H,3H)-二酮及其Ti(IV)、Zn( II)、Fe(III) 和 Pd(II) 复合物在 K562 和 Jurkat 细胞系上。

(6-(cyclohexylamino)-1,3-二甲基-5(2-pyridyl)furo[2,3-d]pyrimidine-2,4(1H,3H)-dione) 缩写为 CDP 合成和表征。该配体的 Ti(IV)、Zn(II)、Fe(III) 和 Pd(II) 金属配合物是通过 Ti(IV)、Zn(II)、Fe(III) 和 Pd 的盐反应制备的(II) 在乙腈中使用 CDP。配体及其配合物的表征通过微量分析、FT-IR、(1)H NMR、(13)C NMR 和紫外-可见光谱进行。所有配合物都通过使用元素分析（C、H、N）、FT-IR、电子光谱和摩尔电导测量的几种技术进行表征。元素分析数据表明化学计量为 1:1 [M:L] 比率形成。摩尔电导测量显示存在 1:1 电解性质的复合物。